This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spencer A, Horvath N, Gibson J, Prince HM, Hermann R, Bashford J et al. Prospective randomized trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphelan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.
Thieblemont C, Dumontet C, Saad H, Roche N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high dose melphelan conditioning and autologous peripheral blood progenitor cell transplantation in patients with multiple myeloma. Bone Marrow transplant 2002; 30: 769–775.
Philips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphelan: a phase 1 study. Biol Blood Marrow Transplant 2004; 10: 473–483.
Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M et al. Amifostine can reduce mucosal damage after high-dose melphelan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Hematol 2000; 110: 300–307.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sastry, P., Bhagwat, R., Biswas, G. et al. Trial of amifostine in autologous stem cell transplant. Bone Marrow Transplant 37, 117–118 (2006). https://doi.org/10.1038/sj.bmt.1705204
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705204